Clinical trials: Melanoma
Epidermal Nevus Syndrome
A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)
KRN23 is a fully human immunoglobulin monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), leading to an increase in serum phosphorus levels.
- Trial name
- ENS (NCT04320316)
- Testing
- Crysvita (burosumab-twza) Treatment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Choroidal Melanoma
Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the…
- Trial name
- NCT00680225
- Testing
- Ranibizumab injection and TTT - ICG based
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- New England Retina Associates
Melanoma
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
The purpose of this clinical research study is to examine the safety and effectiveness (how well the drug works) of two different treatments for patients with melanoma.
- Trial name
- NCT00324155
- Testing
- Ipilimumab, Dacarbazine
- Where
- 127 sites in United States, Argentina and 23 more
- Volunteers
- 681 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Melanoma
Fecal Microbiota Transplant (FMT) in Melanoma Patients
The main goal of this research study is to determine if the fecal microbiota transplant (FMT) improves the body's ability to fight your cancer.
- Trial name
- NCT03341143
- Testing
- Fecal Microbiota Transplant with Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Zarour, Hassane, MD
BRAF Mutant Metastatic Melanoma
BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
This is a phase 1/2 clinical trial with the goal of determining whether the addition of the investigational agent BKM120 to vemurafenib will lead to improved 6-month progression-free survival in patients with BRAFV600E/K mutant…
- Trial name
- NCT01512251
- Testing
- BKM120 Combined with Vemurafenib (PLX4032)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, San Francisco
Melanoma
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
The purpose of this study is to determine the effects of combination treatment of Nivolumab with Ipilimumab followed by Nivolumab monotherapy in patients with previously untreated advanced Melanoma.
- Trial name
- CheckMate 401 (NCT02599402)
- Testing
- Nivolumab, Ipilimumab
- Where
- 111 sites in Australia, Austria and 10 more
- Volunteers
- 533 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with uveal melanoma that has spread to other places in the body (metastatic).
- Trial name
- NCT01585194
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying four different vaccines using melanoma peptides from cytotoxic T cells and…
- Trial name
- NCT00071981
- Testing
- incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine
- Where
- 65 sites in United States
- Volunteers
- 175 people
- Sponsor
- Eastern Cooperative Oncology Group
Melanoma
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
- Trial name
- NCT00429312
- Testing
- JX-594
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Jennerex Biotherapeutics
Melanoma (Skin)
0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma
RATIONALE: Drugs used in chemotherapy, such as pentamidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00729807
- Testing
- pentamidine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Maryland, Baltimore
Malignant Melanoma
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
This open-label single-arm study will evaluate the effect of RO5185426 [RG7204; PLEXXIKON: PLX4032] on the pharmacokinetics of five CYP450 substrates (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam)…
- Trial name
- NCT01001299
- Testing
- Drug cocktail, RO5185426
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Metastatic Melanoma
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Current therapeutic approaches available for patients with advanced-stage melanoma remain inadequate, and existing approaches including those involving immunotherapy with cytokines and/or targeted strategies have resulted in…
- Trial name
- NCT01876212
- Testing
- DC vaccine, Dasatinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Walter J. Storkus
Malignant Melanoma
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or…
- Trial name
- coBRIM (NCT01689519)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 495 people
- Sponsor
- Hoffmann-La Roche
Cancer, Melanoma
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
This was a single-arm, open-label, multi-center, Phase II study to evaluate dabrafenib and trametinib combination therapy in subjects with BRAF V600 mutation-positive, unresectable or metastatic Acral lentiginous or cutaneous…
- Trial name
- NCT02083354
- Testing
- Dabrafenib, Trametinib
- Where
- 13 sites in China, Hong Kong and 3 more
- Volunteers
- 77 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Melanoma
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
This study will evaluate the efficacy and safety of cobimetinib plus atezolizumab in participants with BRAFV600 wild-type melanoma with central nervous system (CNS) metastases and of cobimetinib plus atezolizumab and vemurafenib…
- Trial name
- NCT03625141
- Testing
- Cobimetinib, Atezolizumab, Vemurafenib
- Where
- 22 sites in Brazil, France and 6 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce tumor size and prolong survival in patients with metastatic melanoma (melanoma that has spread beyond the original tumor site).
- Trial name
- NCT00109005
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable Melanoma, Metastatic Melanoma
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
This is a multicenter, open label, Phase 2 study, with 3 parallel cohorts. The aim of the study is to evaluate the efficacy of sotigalimab (APX005M) administered at 2 different schedules to adult participants with unresectable or…
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Cancer, Cancer of Skin
- Trial name
- NCT04337931
- Testing
- sotigalimab
- Where
- 19 sites in Poland, Spain
- Volunteers
- 45 people
- Sponsor
- Apexigen America, Inc.
Metastatic Melanoma, Skin Cancer
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
Background: Some cancer treatments collect a patient s own blood cells to use as specialized cancer-fighting cells. Collected white blood cells known as PBL (peripheral blood lymphocytes) can use to isolate special cells that can…
- Trial name
- NCT01495572
- Testing
- Fludarabine, Cyclophosphamide, Aldesleukin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma
A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma
The main purpose of this trial is to evaluate the safety, tolerability and adverse event profile of pembrolizumab in subjects who have high risk melanoma before and after their standard of care surgical resection, and to collect…
- Trial name
- NCT02434354
- Testing
- pembrolizumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Abramson Cancer Center at Penn Medicine